Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 376 to 390 of 734 results for diabet*

  1. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

    Technology appraisal guidance
    Last updated
    1 May 2025
    View recommendations

    Sections for TA878

  2. How can fetuses at risk of intrauterine death be identified in women with diabetes?

    How can fetuses at risk of intrauterine death be identified in women with diabetes? Any explanatory notes(if applicable) Unexpected...

    Research recommendation
    Published
    9 June 2015

  3. How effective and cost effective are interventions which use either a 'total population' or 'high-risk population' approach to preventing type 2 diabetes among people from black and minority ethnic or lower socioeconomic groups?

    'total population' or 'high-risk population' approach to preventing type 2 diabetes among people from black and minority ethnic or lower...

    Research recommendation
    Published
    9 June 2015

  4. Effectiveness of SGLT2 inhibitors for different ethnic groups: What is the clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes and chronic kidney disease, stratified across different ethnic groups?

    clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes and chronic kidney disease, stratified across...

    Research recommendation
    Published
    24 March 2022

  5. Effectiveness of SGLT2 inhibitors for adults with a urine ACR below 3 mg/mmol: What is the clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes, chronic kidney disease and a urine ACR of less than 3 mg/mmol?

    clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes, chronic kidney disease and a urine ACR of less than...

    Research recommendation
    Published
    24 March 2022

  6. Continuous glucose monitoring in children and young people with type 2 diabetes: What is the effectiveness and cost effectiveness of continuous glucose monitoring devices in children and young people with type 2 diabetes?

    Continuous glucose monitoring in children and young people with type 2 diabetes: What is the effectiveness and cost effectiveness of...

    Research recommendation
    Published
    8 April 2022

  7. The effects of stopping and/or switching drug treatments to control blood glucose levels: In adults with type 2 diabetes, what are the effects of stopping and/or switching drug treatments to control blood glucose levels, and what criteria should inform the decision?

    drug treatments to control blood glucose levels: In adults with type 2 diabetes, what are the effects of stopping and/or switching drug...

    Research recommendation
    Published
    16 December 2021

  8. Long-term outcomes associated with blood glucose lowering agents: In adults with type 2 diabetes, what are the long‑term effects of blood glucose lowering therapies such as dipeptidyl peptidase‑4 (DPP‑4) inhibitors, sodium–glucose cotransporter‑2 (SGLT2) inhibitors and meglitinides?

    outcomes associated with blood glucose lowering agents: In adults with type 2 diabetes, what are the long‑term effects of blood glucose...

    Research recommendation
    Published
    16 December 2021

  9. Non-metformin-based drug treatment combinations to control blood glucose levels: In adults with type 2 diabetes, what treatment combinations (for example, glucagon‑like peptide‑1 [GLP‑1] mimetics and insulin combination therapy with meglitinides) are most effective when initial drug treatment with non‑metformin monotherapy fails to adequately control blood glucose levels?

    treatment combinations to control blood glucose levels: In adults with type 2 diabetes, what treatment combinations (for example,...

    Research recommendation
    Published
    16 December 2021

  10. Further research is recommended to resolve uncertainties about the cost effectiveness of fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema. This should focus on a group of patients whose condition is unresponsive to other available therapies, and include measures of efficacy and health-related quality of life. Research should focus on identifying appropriate utility values, taking into account the utility values for different levels of visual acuity and the relative relationship in utility values from treating the best-seeing and the worse-seeing eye. The appropriateness of generalising utility values from one group of eye conditions to another group would also be of value.

    fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema. This should focus on a group of...

    Research recommendation
    Published
    9 June 2015

  11. Lifestyle interventions:- How effective and cost effective are different types (and levels and frequency) of physical activity in reducing short- and long-term blood glucose levels and preventing or delaying type 2 diabetes? How does this vary for different subgroups, for example, different black and minority ethnic groups and people of different ages, for example, aged 18–24, 25–39 and 75 and over?

    short- and long-term blood glucose levels and preventing or delaying type 2 diabetes? How does this vary for different subgroups, for...

    Research recommendation
    Published
    9 June 2015

  12. Lifestyle interventions:- How effective and cost effective are different types of dietary regime in reducing short- and long-term blood glucose levels and preventing or delaying type 2 diabetes? How does this vary for different subgroups, for example, African-Caribbean and black African and other minority ethnic groups and for people of different ages, for example, aged 18–24, 25–39 and 75 and over?

    short- and long-term blood glucose levels and preventing or delaying type 2 diabetes? How does this vary for different subgroups, for...

    Research recommendation
    Published
    9 June 2015

  13. Lifestyle interventions:- Which components of an intensive lifestyle-change programme contribute most to the effectiveness and cost effectiveness of interventions to prevent or delay type 2 diabetes in those at high risk? How does this vary for different black and minority ethnic groups, for people of different ages for example, aged 18–24, 25–39 and 75 and over, and for vulnerable adults?

    effectiveness and cost effectiveness of interventions to prevent or delay type 2 diabetes in those at high risk? How does this vary for...

    Research recommendation
    Published
    9 June 2015

  14. What is the effectivness of stains and/or other lipid-lowering treatment in people with type 1 diabetes?

    effectivness of stains and/or other lipid-lowering treatment in people with type 1 diabetes? Any explanatory notes(if applicable) For a...

    Research recommendation
    Published
    3 May 2024

  15. Vulnerable groups:- What are the most effective and cost-effective methods for identifying, assessing and managing the risk of type 2 diabetes among high-risk, vulnerable adults? This group includes: frail older adults, homeless people, those with severe mental illness, learning or physical disabilities, prisoners, refugees, recent migrants and travellers.

    cost-effective methods for identifying, assessing and managing the risk of type 2 diabetes among high-risk, vulnerable adults? This...

    Research recommendation
    Published
    9 June 2015